Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
2.
Int Immunopharmacol ; 65: 129-139, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30316071

ABSTRACT

Nutraceuticals are compounds that serve as nutrition with an easy accessibility and favourable safety profile. Recent studies showed their potential activity on osteoarthritis (OA) inflammation and cartilage metabolism. We investigated the effect of methylsulfonylmethane (MSM) and mobilee in human OA chondrocyte cultures exposed to interleukin (IL)-1ß. OA cartilage was obtained from femoral heads of five patients undergoing total replacement surgery. Chondrocytes were incubated with mobilee (200 and 500 µM) and MSM (2000 and 6000 µM) in presence of IL-1ß (10 ng/mL) and nuclear factor (NF)-κB inhibitor (BAY 11-7082, 1 µM), for 24 and 48 h. Viability and apoptosis were performed by MMT and flow cytometry. The metalloproteinase (MMP)-1,-3,-13 and type II collagen (Col2a1) were analyzed by qRT-PCR and ELISA, and NF-κB activation by immunofluorescence. IL-1ß stimulus determined a significant regulation of survival, apoptotic ratio, as well as of gene expression and serum levels of MMP-1,-3,-13 and Col2a1 in OA chondrocytes compared to baseline. Mobilee and MSM incubation significantly reversed the effect of IL-1ß. IL-1ß significantly induced NF-κB p50 nuclear translocation, which was significantly counteracted by the pre-treatment of OA chodrocytes with the tested compounds. BAY11-7082 significantly modulated MMPs and Col2a1 expression respectively to basal state. Co-treatment of IL-1ß with mobilee, MSM and BAY11-7082 didn't cause changes of MMPs or Col2a1 beyond that caused by each single treatment. We demonstrated that MSM and mobilee have a beneficial effect on OA chondrocytes metabolism, probably due to the modulation of NF-κB pathway, providing a powerful rationale for the use of these substances in OA treatment.


Subject(s)
Chondrocytes/drug effects , Dimethyl Sulfoxide/pharmacology , Hyaluronic Acid/pharmacology , Interleukin-1beta/metabolism , NF-kappa B/metabolism , Sulfones/pharmacology , Aged , Cell Survival , Chondrocytes/metabolism , Gene Expression Regulation/drug effects , Humans , Interleukin-1beta/genetics , Matrix Metalloproteinases/metabolism , Middle Aged , NF-kappa B/genetics , Osteoarthritis/metabolism , Signal Transduction/drug effects
3.
Metab Brain Dis ; 32(1): 203-210, 2017 02.
Article in English | MEDLINE | ID: mdl-27585464

ABSTRACT

Mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo A) is a neurodegenerative lysosomal storage disorder caused by the deficiency of sulphamidase enzyme (SGSH) leading to accumulation of heparan sulfate (HS). We quantitatively and structurally characterize primary stored HS and other glycosaminoglycans (GAGs) possibly accumulated through a secondary storage in brain, liver, kidney and lung of MPS IIIA mouse model. This analysis was also performed in MPS IIIA mice upon the intravenous treatment with an engineered human sulphamidase (chimeric hSGSH) capable to increase its secretion from the liver and to cross the blood-brain barrier. MPS IIIA animals showed a huge accumulation of HS, from ~15 up to ~24-times higher than wild type and also of hyaluronic acid (HA) (from 2.5 up to ~5.0-times more) and chondroitin sulfate (CS)/dermatan sulfate (DS) (from ~2 up to ~5-times more) in all studied organs. We also observed a significant increase in the overall HS charge density and in particular of 2-O-sulfation in MPS IIIA mice organs. 8 months after a systemic treatment with an engineered SGSH, the enzyme was highly efficient in the reduction of all accumulated GAGs in liver, brain and lung up to values of wild type mice. On the contrary, even if reduced, GAGs levels still remained significantly elevated in kidney. Overall data obtained by this detailed analysis of GAGs in the different organs of affected and treated animals with chimeric hSGSH may have implications for the evaluation of an effective therapeutic option of MPS IIIA and for the reduction of related neuropathology.


Subject(s)
Blood-Brain Barrier/drug effects , Brain/drug effects , Glycosaminoglycans/metabolism , Hydrolases/pharmacology , Mucopolysaccharidosis III/metabolism , Animals , Blood-Brain Barrier/metabolism , Brain/metabolism , Disease Models, Animal , Glycosaminoglycans/blood , Mice , Mucopolysaccharidosis III/blood , Mucopolysaccharidosis III/genetics
4.
Metab Brain Dis ; 30(6): 1343-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26016623

ABSTRACT

Mucopolysaccharidoses (MPS) are characterized by mental retardation constantly present in the severe forms of Hurler (MPS I), Hunter (MPS II) and Sanfilippo (MPS III) diseases. On the contrary, mental retardation is absent in Morquio (MPS IV) and Maroteaux-Lamy (MPS VI) diseases and absent or only minimal in the attenuated forms of MPS I, II and III. Considering that MPS patients affected by mental disease accumulate heparan sulfate (HS) due to specific enzymatic defects, we hypothesized a possible correlation between urinary HS-derived glucosamine (GlcN) accumulated in tissues and excreted in biological fluids and mental retardation. 83 healthy subjects were found to excrete HS in the form of fragments due to the activity of catabolic enzymes that are absent or impaired in MPS patients. On the contrary, urinary HS in 44 patients was observed to be composed of high molecular weight polymer and fragments of various lengths depending on MPS types. On this basis we correlated mental retardation with GlcN belonging to high and low molecular weight HS. We demonstrate a positive relationship between the accumulation of high molecular weight HS and mental retardation in MPS severe compared to attenuated forms. This is also supported by the consideration that accumulation of other GAGs different from HS, as in MPS IV and MPS VI, and low molecular weight HS fragments do not impact on central nervous system disease.


Subject(s)
Glucosamine/urine , Heparitin Sulfate/urine , Intellectual Disability/genetics , Intellectual Disability/metabolism , Mucopolysaccharidoses/genetics , Mucopolysaccharidoses/psychology , Adolescent , Adult , Child , Child, Preschool , Female , Glucosamine/chemistry , Heparitin Sulfate/chemistry , Humans , Infant , Male , Molecular Weight , Mucopolysaccharidosis I/genetics , Mucopolysaccharidosis I/psychology , Mucopolysaccharidosis III/genetics , Mucopolysaccharidosis III/psychology , Reference Values , Young Adult
5.
Int J Immunopathol Pharmacol ; 27(1): 97-102, 2014.
Article in English | MEDLINE | ID: mdl-24674683

ABSTRACT

Osteopontin (OPN) is an extracellular matrix protein implicated in bone remodeling, but it presents also pro-inflammatory and pro-fibrotic properties. OPN expression also occurs upon exposure of cells to classical mediators of acute inflammation such as tumor necrosis growth factor alpha (TNF-alpha) and interleukin-1 beta (IL-1beta), as well as fibrogenic cytokines such as transforming growth factor beta (TGF-beta), although a detailed understanding of these regulatory pathways is still unknown. Plasma OPN levels in both limited and diffuse systemic sclerosis patients (lSSc and dSSc) were statistically higher compared to those of control subjects. Immunohistology demonstrated that high TGF-beta levels, alpha smooth muscle actin (alphaSMA) levels and consequently high OPN levels were found in the affected skin of sclerodermic patients (lSSc and dSSc) compared to levels found in healthy skin. In order to better understand how OPN interferes with the fibrotic process, healthy skin fibroblasts were treated for 24 and 48 hours with bleomycin and with endothelin-1 (ET-1) plus TGF-beta in order to induce the fibrogenesis. After 48 hours of stimulation, healthy treated fibroblasts showed statistically increased alphaSMA levels (index of differentiation into myofibroblasts) and simultaneously statistically increased OPN levels compared to healthy untreated ones. This study demonstrates that OPN levels increase simultaneously with the increasing of alphaSMA levels, therefore it is reasonable to hypothesize that OPN interferes in the pathogenesis of Systemic Sclerosis in the early stage of fibroblast differentiation process.


Subject(s)
Actins/metabolism , Cell Differentiation , Fibroblasts/metabolism , Osteopontin/metabolism , Scleroderma, Systemic/etiology , Bleomycin/pharmacology , Blotting, Western , Case-Control Studies , Cells, Cultured , Endothelin-1/pharmacology , Enzyme-Linked Immunosorbent Assay , Female , Fibroblasts/drug effects , Fibroblasts/pathology , Humans , Immunohistochemistry , Middle Aged , Osteopontin/blood , Scleroderma, Systemic/blood , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/pathology , Transforming Growth Factor beta/pharmacology
7.
J Biol Regul Homeost Agents ; 27(2): 455-62, 2013.
Article in English | MEDLINE | ID: mdl-23830395

ABSTRACT

Systemic sclerosis (or scleroderma) is an autoimmune disease characterized by skin and internal organ fibrosis, caused by microvascular dysfunction. The microvascular damage seems to be a consequence of an endothelial autoimmune response, followed by activation of the inflammatory cascade and massive deposition of collagen. Endothelin-1 (ET-1) contributes to the inflammatory and fibrotic processes by increasing the concentration of pro-inflammatory and pro-fibrotic cytokines, and it is considered one of the most relevant mediators of vascular damage in scleroderma. It is indeed found in very high concentration in serum of sclerodermic patients. Moreover, in these pathological conditions there is an increased expression of ET-1 receptors (ETA and ETB), which mediate the detrimental action of ET-1, and often a change of ETA/ETB ratio. The aim of the present study is to evaluate the in vitro effect of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist, and its major metabolite (ACT-132577) on alpha smooth muscle actin (alphaSMA) expression, evaluated on dermal fibroblasts from healthy subjects and on dermal fibroblasts from lesional and non-lesional skin from sclerodermic patients. The combination of macitentan and its major metabolite reduced the levels of αSMA after 48 h in sclerodermic fibroblasts from lesional skin. No relevant changes in αSMA levels were found in fibroblasts from non-lesional skin, whose behavior is similar to that of dermal fibroblasts from healthy patients.


Subject(s)
Endothelin A Receptor Antagonists , Endothelin B Receptor Antagonists , Pyrimidines/pharmacology , Scleroderma, Systemic/drug therapy , Skin/pathology , Sulfonamides/pharmacology , Actins/analysis , Aged , Female , Fibrosis , Humans , Middle Aged , Pyrimidines/therapeutic use , Scleroderma, Systemic/pathology , Sulfonamides/therapeutic use
8.
Scand J Rheumatol ; 41(5): 391-5, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23043266

ABSTRACT

OBJECTIVES: Relaxin (RLX) is involved in extracellular matrix and collagen remodelling. The therapeutic role of the circulating isoform RLX-2 as an anti-fibrotic factor in systemic sclerosis (SSc) has been investigated. Several RLX family peptide receptors (RXFPs) are recognized in humans: RLX-2 is a ligand for RXFP1/LGR7 and RXFP2/LGR8. The aim of this study was to define the pattern of expression of LGR7 in different types of human skin cells and to compare normal skin with lesional and unaffected skin from patients with limited SSc (lSSc). METHOD: We analysed RXFP1 immunolocalization on skin biopsies and cultured fibroblasts from lSSc patients and control subjects. Western blot analysis was carried out on fibroblast lysates. RESULTS: RXFP1 showed cytoplasmic localization on skin cells from control subjects and non-lesional skin from lSSc patients: keratinocytes, gland epithelial cells, endothelium, smooth muscle cells, and fibroblasts. Immunogold electron microscopy confirmed a diffuse epithelial cytoplasmic localization of RXFP1. A substantially lower RXFP1 expression was observed in scleroderma skin, with a lack of staining in most cells. Occasional weak reactivity was observed in cultured scleroderma fibroblasts, while control fibroblasts showed a diffuse cytoplasmic immunoreactivity of RXFP1, confirmed by Western blot analysis. CONCLUSIONS: The decreased cellular expression of RLX-2 receptor RXFP1 in scleroderma skin might represent a pro-fibrotic factor and contribute to the substantial inefficacy of RLX treatment in SSc, as reported in the literature. The pathophysiology of the decrease in RXFP1 may be linked to high RLX-2 serum levels previously detected in SSc, but it has yet to be elucidated.


Subject(s)
Fibroblasts/metabolism , Receptors, G-Protein-Coupled/metabolism , Receptors, Peptide/metabolism , Scleroderma, Systemic/metabolism , Skin/metabolism , Aged , Cells, Cultured , Female , Fibroblasts/pathology , Fibrosis/metabolism , Fibrosis/pathology , Humans , Middle Aged , Scleroderma, Systemic/pathology , Skin/pathology
9.
Osteoarthritis Cartilage ; 19(11): 1373-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21884808

ABSTRACT

OBJECTIVE: Rodent models of osteoarthritis and rheumatoid arthritis are useful tools to study these disease processes. Adjuvant arthritis (AAR) is a model of polyarthritis widely used for preclinical testing of antiarthritis substances. We report the effect of two different doses of highly purified chondroitin sulfate (CS) pharmaceutical grade in the AAR animal model after oral administration. DESIGN: AAR was induced by a single intradermal injection of heat-inactivated Mycobacterium butyricum in incomplete Freund's adjuvant. The experiments included healthy animals, untreated arthritic animals, arthritic animals having been administered 300 or 900 mg/kg of CS daily, 14 days before AAR induction until the end of the experiment (day 28), arthritic animals having been administered 300 or 900 mg/kg of CS daily, from day 1 until the end of the experiment. RESULTS: CS was capable of significantly reducing the severity of arthritis along with oxidative stress, a consequence of chronic inflammatory processes occurring in AAR. The CS pre-treatment regimen was effective throughout the whole subacute phase, while treatment from day 1 proved effective only in the chronic period. The effects were confirmed by improved total antioxidant status and γ-glutamyltransferase activity. CS administered under a pre-treatment regimen was also able to reduce the production of pro-inflammatory cytokines, C-reactive protein in plasma, phagocytic activity and the intracellular oxidative burst of neutrophils. CONCLUSIONS: CS proved to be effective in slowing down AAR development and in reducing disease markers, thus supporting its beneficial activity as a drug in humans.


Subject(s)
Arthritis, Experimental/drug therapy , Chondroitin Sulfates/pharmacology , Animals , Antioxidants/metabolism , C-Reactive Protein/analysis , Chondroitin Sulfates/administration & dosage , Cytokines/metabolism , Disease Models, Animal , Hindlimb , Male , Neutrophils/metabolism , Oxidative Stress/drug effects , Phagocytes/metabolism , Rats , Rats, Inbred Lew , gamma-Glutamyltransferase/metabolism
11.
Curr Alzheimer Res ; 7(2): 150-7, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19860722

ABSTRACT

A key event in Alzheimer's disease (AD) pathogenesis is the formation of insoluble peptides beta-amyloid aggregates and this process is favoured by a condition of hyperhomocysteinemia. To date, there is growing evidence that implicates glycosaminoglycans (GAGs) in the pathophysiology of amyloidosis but no data are available on the characterization of brain GAGs involved in the enhancing beta-amyloid fibrillogenesis in relationship to their structure and physico-chemical properties. Furthermore, few studies have been performed on the relationship between hyperhomocysteinemia and extracellular matrix (ECM) modifications. The aim of this study was to evaluate the amount and chemical structure of GAGs in rat striatal areas where beta-amyioid fibrillogenesis was induced, and in conditions of hyperhomocysteinemia. The intrastriatal injection of beta-amyloid produced a significant decrease (-40.8%) in the hyaluronic acid (HA) percentage and an increase (+14.5%) in the dermatan sulfate (DS) with a total charge density increasing of 14.9%. A significant decrease (-19.5%) in the HA percentage and an increase (+6.9%) in the DS % was also observed in striata obtained from the hyperhomocysteinemic animals. The total charge density increased by 6.8%. Quite the same trend was observed in rats after intrastriatal injection of beta-amyloid and in a condition of hyperhomocysteinemia. The observed increase of DS concentration and the correspondent decrease of the nonsulfated polymer HA after in vivo treatment with beta-amyloid and in a condition of hyperhocysteinemia support the hypothesis that an increase in local production of sulfated GAGs may reduce beta-amyloid neurotoxicity. However, the consequent modification of the ECM network might impair the extracellular diffusion pathways of different signal molecules and participate in the progression of AD.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Corpus Striatum/metabolism , Extracellular Matrix/metabolism , Glycosaminoglycans/metabolism , Hyperhomocysteinemia/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/toxicity , Animals , Corpus Striatum/pathology , Corpus Striatum/physiopathology , Dermatan Sulfate/metabolism , Hyaluronic Acid/metabolism , Hyperhomocysteinemia/pathology , Male , Plaque, Amyloid/metabolism , Plaque, Amyloid/pathology , Rats , Rats, Sprague-Dawley , Sulfates/metabolism
14.
J Clin Pathol ; 62(5): 442-7, 2009 May.
Article in English | MEDLINE | ID: mdl-19139036

ABSTRACT

AIMS: (a) To evaluate tissue eosinophil density, location of eosinophil cytotoxic products, histopathological muscle changes and inflammatory cell types in different eosinophilia-associated myopathies that are clinicopathologically heterogeneous. (b) To determine the immunohistological range of tissue eosinophil density in non-eosinophilic inflammatory myopathies. METHODS: Muscle biopsy specimens from seven patients with blood and/or tissue eosinophilia and clinicolaboratory myopathic signs (five chronic course myopathies, one subacute onset fasciitis/myositis, one acute myositis), and from 18 non-eosinophilic inflammatory myopathies, underwent routine staining, inflammatory infiltrate immunophenotyping, immunostaining for eosinophil major basic protein (MBP) and transmission electron microscopy examination. Eosinophil and total inflammatory cell counts were statistically analysed. RESULTS: Histological examination showed occasional or no infiltrating eosinophils in all cases. MBP staining showed that tissue eosinophil density and percentages in eosinophilia-associated myopathies were significantly higher than in idiopathic myositides. Extracellular MBP diffusion, the hallmark of eosinophil cytotoxicity, was recurrent on sarcolemma and endothelium. Electron microscopy showed eosinophils close to sarcolemma, abundant mast cells, and capillary endothelial swelling. Immunostaining detected a higher mean eosinophil density in idiopathic myositides than previously assessed histologically. CONCLUSIONS: MBP immunohistology on skeletal muscle, previously performed only for acute eosinophilic polymyositis, suggests that eosinophil-mediated injury of muscle cells may occur in a wider spectrum of less aggressive eosinophilia-associated myopathies than previously thought. As conventional histology is likely to underestimate this leucocyte subset, MBP staining may be a useful tool in the analysis of tissue infiltration of eosinophils as a possible treatment target.


Subject(s)
Eosinophil Major Basic Protein/metabolism , Eosinophilia/pathology , Muscular Diseases/pathology , Adult , Aged , Biomarkers/blood , Biopsy , Eosinophilia/immunology , Eosinophilia/metabolism , Eosinophils/ultrastructure , Female , Humans , Immunophenotyping , Male , Mast Cells/ultrastructure , Middle Aged , Muscle, Skeletal/immunology , Muscle, Skeletal/metabolism , Muscle, Skeletal/ultrastructure , Muscular Diseases/immunology , Muscular Diseases/metabolism , Myositis/immunology , Myositis/metabolism , Myositis/pathology
15.
Lymphology ; 41(1): 29-39, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18581956

ABSTRACT

We investigated lymphatic morphology and expression of endothelin (ET-1) axis molecules in human eyelids affected by an inflammatory state (chalazion) and an age-related degenerative condition (dermatochalasis). Lymphatics were immunohistologically detected by D2-40/LYVE-1 staining. Absorbing lymphatic vessels were localized in papillary dermis and around skin appendages with distinctive morphology. In chalazion, D2-40 reactive flattened lymphatic profiles were compressed by inflammatory infiltrate; in dermatochalasis, large fully opened lymphatics were observed, with a significantly wider total area (lymphatic lumina/200x field; p < 0.05). The lymphatic density (number/200x field) in the two groups was within the same range. Lymphatic dilation is possibly dependent on reduction and fragmentation of the dermal elastic network as well as of oxytalanic fibers in the papillary dermis of dermatochalasis, as shown by Weigert's reaction. Multifunctional peptide ET-1, involved in vasomotion, inflammation and connective proliferation, was faintly and discontinuously localized on lymphatics, as was its type A receptor. In contrast, the consistent expression of type B receptor indicates that lymphatic endothelium is a physiological target for ET-1, whose effects are modulated by multiple pathophysiological conditions. Thus, vasoactive factors play a role in the physiology of richly vascularized eyelids, and therefore, morphofunctional characterization of lymphatic vessels may be useful in suggesting treatment options.


Subject(s)
Chalazion/pathology , Eyelid Diseases/pathology , Eyelids/pathology , Lymphatic Vessels/pathology , Adult , Aged , Antibodies, Monoclonal/analysis , Antibodies, Monoclonal, Murine-Derived , Chalazion/metabolism , Endothelin-1/analysis , Eyelid Diseases/metabolism , Eyelids/chemistry , Female , Humans , Immunohistochemistry , Lymphatic Vessels/chemistry , Male , Middle Aged , Vesicular Transport Proteins/analysis
16.
Histol Histopathol ; 22(12): 1343-54, 2007 12.
Article in English | MEDLINE | ID: mdl-17701914

ABSTRACT

Endothelin-1 (ET-1), a potent vasoconstrictor peptide, is involved in several functions of eye pathophysiology, such as regulation of intraocular tension and retinal reactive vasoconstriction. As ET-1 pro-inflammatory and fibrosing activity is emerging in different fields of pathology, we investigated the expression of ET-1 and endothelin-converting enzyme-1 (ECE-1) in chalazia, granulomatous lesions of the eyelid. ET-1 and ECE-1 were analyzed by immunohistochemistry (IHC) in twenty surgically removed chalazia, with regard to expression in eyelid structures and inflammatory infiltrate. Phenotype of ET-1 expressing inflammatory cells was established by double immunofluorescence. The cellular localization of prepro-ET-1 (pp-ET-1) mRNA and ECE-1 mRNA was studied by nonisotopic in situ hybridization (ISH). Neutrophils (PMNs), macrophages and T-lymphocytes were scattered in stroma, around alveoli and grouped in lipogranulomas. PMNs, macrophages, basal epithelium of meibomian adenomers and central ducts immunostained for ET-1. ECE-1 protein was found in meibomian adenomers, conjunctival epithelium, tarsal mucous glands and in inflammatory cells. Hybridization signals for pp-ET-1 mRNA and ECE-1 mRNA were recognized in healthy and degenerating meibomian ducts, adenomers, inflammatory cells, as well as in vessel walls. ECE-1 mRNA was also present in conjunctival epithelium and Henle's crypts. Our findings suggest that the multifunctional peptide ET-1 may have a role in molecular genesis of tissue damage in chalazia. ET-1 cytokine activity is likely to support the migration of inflammatory cells and the setting of lipogranulomas; ET-1 stimulation might contribute to proliferation of fibroblasts and collagen synthesis. ET-1 upregulation on meibomian adenomers and ducts may further enhance granulomas formation by stimulating lipid release.


Subject(s)
Aspartic Acid Endopeptidases/biosynthesis , Endothelin-1/biosynthesis , Eyelids/metabolism , Granuloma/metabolism , Immunohistochemistry/methods , In Situ Hybridization/methods , Metalloendopeptidases/biosynthesis , Adolescent , Adult , Aged , Endothelin-Converting Enzymes , Female , Gene Expression Regulation , Humans , Inflammation/metabolism , Male , Middle Aged
17.
J Pharm Biomed Anal ; 44(5): 1056-63, 2007 Sep 03.
Article in English | MEDLINE | ID: mdl-17553647

ABSTRACT

Changes in dynamic viscosity of the solutions of a high-molar-mass hyaluronan (HA) were monitored using a rotational viscometer. The degradative conditions generated in the HA solutions by a system comprising ascorbate plus Cu(II) plus H(2)O(2) were studied either in the presence or absence of a drug--naproxen or acetylsalicylic acid. Continual decrease of the dynamic viscosity of HA solution was indicative of the polymer degradation. Addition of the drug retarded/inhibited the HA degradation in a concentration-dependent manner. The characteristics of the fragmented polymers were investigated by FT-IR spectroscopy and by two different liquid chromatographic techniques, namely by size-exclusion chromatography equipped with a multi-angle light scattering photometric detector and by high-performance liquid chromatography connected on-line to a spectrofluorometer.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/chemistry , Ascorbic Acid/chemistry , Aspirin/pharmacology , Copper/chemistry , Hyaluronic Acid/antagonists & inhibitors , Hyaluronic Acid/chemistry , Naproxen/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Aspirin/chemistry , Cations, Divalent/chemistry , Chromatography, Gel , Chromatography, High Pressure Liquid , Hydrogen Peroxide/chemistry , Molecular Structure , Molecular Weight , Naproxen/chemistry , Oxidants/chemistry , Oxidation-Reduction , Solutions/chemistry , Spectrometry, Fluorescence , Spectrophotometry, Ultraviolet , Spectroscopy, Fourier Transform Infrared , Viscosity/drug effects
18.
J Endocrinol Invest ; 29(4): 337-41, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16699300

ABSTRACT

The present study investigated whether trophoblast, decidua and fetal membranes express nerve growth factor (NGF) mRNA and peptide. Tissue specimens were collected in the first and third trimester of pregnancy from women undergoing voluntary pregnancy interruption (no.= 6; from 8 to 12 gestational weeks) and from women having an elective caesarean section at term (no.= 6; week 39-40 of pregnancy). Using reverse transcriptase-polymerase chain reaction (RT-PCR), trophoblast, amnion/chorion and maternal decidua showed the expression of NGF mRNA both in early gestation and at term. By immunohistochemistry, the immunoreactive NGF was found in the cyto and syncytial trophoblast cells, chorionic mesodermic cells and in decidua. Vessel endothelial cells were stained in maternal compartments, while fetal vessels were unstained. These results, showing the expression and localization of NGF, support the current concept that human placenta is a potent neuroendocrine organ throughout gestation.


Subject(s)
Decidua/metabolism , Extraembryonic Membranes/metabolism , Nerve Growth Factor/biosynthesis , Nerve Growth Factor/genetics , RNA, Messenger/metabolism , Trophoblasts/metabolism , Female , Humans , Pregnancy , Pregnancy Trimester, First/physiology , Pregnancy Trimester, Third/physiology , Reverse Transcriptase Polymerase Chain Reaction
19.
Lymphology ; 39(4): 171-3, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17319628

ABSTRACT

Lymphatics were detected in the epineurium of the human sural nerve by D-240 immunostaining and confirmed by ultrastructural examination.


Subject(s)
Antibodies, Monoclonal , Lymphatic Vessels/anatomy & histology , Sural Nerve/anatomy & histology , Antibodies, Monoclonal, Murine-Derived , Humans , Immunoenzyme Techniques , Lymphatic Vessels/ultrastructure , Sural Nerve/ultrastructure
20.
Osteoarthritis Cartilage ; 11(6): 433-41, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12801483

ABSTRACT

OBJECTIVE: Chondroitin sulfate (CS) has proven to be a valuable therapeutic tool as a symptomatic slow-acting drug for the treatment of osteoarthritis after oral administration. The aim of this study was to assess the absorption of CS of ichthyic origin after oral administration to 20 healthy male volunteers. DESIGN: Ichthyic origin CS (from shark cartilage, 4 g) was orally administered to 20 healthy human volunteers, and then extracted and purified from plasma over a 48 h period. The polysaccharide absorbed by oral route was characterized and quantified by agarose-gel electrophoretic technique, and densitometric scanning. In addition, the percentage of constituent disaccharides and charge density were measured. RESULTS: After oral administration, ichthyic CS plasma levels increased (more than 120%) with a peak concentration at 8.7h, with the increase reaching significance from 4 to 16 h. A significant decrease in the relative amount of non-sulfated disaccharide was measured (reaching the minimum relative percentage of 30.86+/-20.79% at 8h). At the same time, 4-sulfated disaccharide increased to a maximum of 51.91+/-25.91% at 6h, and 6-sulfated and disulfated disaccharides appeared in blood, reaching maximum concentrations of 15.24+/-16.60% at 8h and 2.93+/-4.82% at 12h, respectively. Concomitantly, the mean charge density rose from 0.40+/-0.14 at predose to a maximum of 0.72+/-0.22 and 0.72+/-0.21 measured 8 and 12h after ichthyic CS administration. CONCLUSIONS: Ichthyic CS is absorbed slowly, with a t(max)=8.7+/-4.5h and the C(max)averaged 4.87+/-2.05 microg/ml. The differences in the absorption and bioavailability of the various CS formulations is strongly influenced by the structure and characteristics, such as molecular mass, charge density, and cluster of disulfated disaccharides, of the parental molecules.


Subject(s)
Chondroitin Sulfates/pharmacokinetics , Osteoarthritis/blood , Absorption , Adult , Biological Availability , Chondroitin Sulfates/administration & dosage , Electrophoresis, Agar Gel/methods , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...